Cerium oxide NPs mitigate the amyloid formation of α-synuclein and associated cytotoxicity

Aim: Among therapeutic proposals for amyloid-associated disorders, special attention has been given to the exploitation of nanoparticles (NPs) as promising agents against aggregation.

Methods: In this paper, the inhibitory effect of cerium oxide (CeO$_2$) NPs against α-synuclein (α-syn) amyloid formation was explored by different methods such as Thioflavin T (ThT) and 8-anilinonaphthalene-1-sulfonic acid (ANS) fluorescence spectroscopy, Congo red adsorption assay, circular dichroism (CD) spectroscopy, transmission electron microscopy (TEM), and bioinformatical approaches. Also, the cytotoxicity of α-syn amyloid either alone or with CeO$_2$ NPs against neuron-like cells (SH-SY5Y) was examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), flow cytometry, and quantitative real-time polymerase chain reaction (Bax and Bcl-2 gene expression) assays.

Results: ThT and ANS fluorescence assays indicated that CeO$_2$ NPs inhibit the formation of aggregated species and hydrophobic patches of α-syn in amyloidogenic conditions, respectively. Congo red and CD assays demonstrated that CeO$_2$ NPs reduce the formation of amyloid species and β-sheets structures of α-syn molecules, respectively. TEM investigation also confirmed that CeO$_2$ NPs limited the formation of well-defined fibrillar structures of α-syn molecules. Molecular docking and dynamic studies revealed that CeO$_2$ NPs could bind with different affinities to α-syn monomer and amyloid species and fibrillar structure of α-syn is disaggregated in the presence of CeO$_2$ NPs. Moreover, cellular assays depicted that CeO$_2$ NPs mitigate the cell mortality, apoptosis, and the ratio of Bax/Bcl-2 gene expression associated with α-syn amyloids.

Conclusion: It may be concluded that CeO$_2$ NPs can be used as therapeutic agents to reduce the aggregation of proteins and mitigate the occurrence of neurodegenerative diseases.

Keywords: cerium oxide, nanoparticle, amyloid, cytotoxicity, spectroscopy, cellular assay, inhibition

Introduction

In neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s disease, abnormal changes in specific protein structures cause their aggregation and subsequent accumulation in nerve cells, which can destroy neurons. One of the most important neuronal proteins is α-synuclein (α-syn) that their aggregations result in formation of Lewy body filaments associated with impaired nerve functioning. Indeed, these filaments are heterogeneous and rich in β-sheet structures along with hydrophobicity and tinctorial attributes. The α-syn filaments stimulate high cytotoxicity by increasing reactive oxygen species (ROS) and altering or damaging the structure of the nerve cells through apoptosis. The most important factors affecting α-
syn fibrillation are: 1) structural factors including modification of hydrophilic headgroups and hydrophobic tails, changing surface charge of protein, presence of aromatic amino acids, and 2) environmental factors including changes of pH, high temperature, protein concentration, oxidative stress, and the peptide chain mutations. α-Syn is the most common protein in the nervous system with 140 amino acids (14 kDa) that consist 1% of the total protein in the cytosolic region of the brain. Hence, to stop the growth and accumulation of α-syn in nerve cells, various methods such as organic or non-organic compounds, small peptides, and gene therapy have been exploited. In this field, due to the enormous impact of nanoscience on medical and therapeutic services, the effect of nanomaterials on controlling the aggregation of α-syn has been given special attention. Unlike gold (Au) nanoparticles (NPs) that induce α-syn fibrillation by influencing both the nucleation and growth phases, iron NPs, and even carbon NPs have been shown to prevent the formation of β-sheet fibrillation. Besides, it has been revealed that titanium dioxide (TiO₂) NPs cause α-syn fibrillation, whereas silicon oxide (SiO₂) NPs and Tin oxide (SnO₂) NPs do not affect α-syn fibrillation. While, Wu, Wang, Sun, Xue previously demonstrated that SiO₂ NPs cause α-syn aggregation through induction of oxidative stress.

Therefore, the effects of nanomaterials on protein aggregation are not fully understood, and conflicting results have been reported about inhibitory effects of NPs against protein fibrillation. Also, the application of NPs as therapeutic agents is still obscure due to cytotoxic variation based on their physicochemical properties. Cerium oxide (CeO₂) NPs shows antioxidant features derived from their superoxide dismutase (SOD)- and catalase (CAT)-like activities in vitro and in vivo. In general, CeO₂ NPs due to the surface self-regeneration, which depends on redox-cycling between Ce³⁺ and Ce⁴⁺ conditions, and vacancy of oxygen in the lattice structure, can be used in medical activities to remove ROS. Although, the experiments showed that CeO₂ NPs could have antioxidant features, the lack of CeO₂ NPs in the human body limits their use in biomedical applications due to the probable occurrence of systematic toxicity. Hence, in this study, the inhibitory effects of CeO₂ NPs against the amyloid formation of α-syn were investigated by different spectroscopic and bioinformatical approaches. Afterwards, the cytotoxicity of α-syn amyloid either alone or in the presence of CeO₂ NPs was studied against SH-SY5Y cells.

Materials and methods
Materials
α-Syn, Thioflavin T (ThT), 8-anilinonaphthalene-1-sulfonic acid (ANS), Congo red, Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM: F12), fetal bovine serum (FBS), L-glutamine, penicillin, streptomycin, and MTT were purchased from Sigma Co. (St. Louis, MO, USA). CeO₂ NPs, purity: 99.97%, APS: 10–30 nm, SSA: 30–50 m²/g, bulk density: ~0.8–1.1 g/cm³, and true density: 7.132 g/cm³ were purchased from US Research Nanomaterials, Inc. (Houston, USA) and well characterized by different approaches in our previous paper.

Methods
CeO₂ NP preparation
CeO₂ NPs with defined concentration was freshly solubilized in 1% (v/v) DMSO/water, sonicated for 30 mins by a sonicator probe (Misonix-S3000, USA) and were kept at ambient temperature. To reveal that NPs do not compromise ThT, Tyr, Congo red, and circular dichroism (CD) signals, all experiments were performed in the presence of probes and NPs concentrations in agreement with those of diluted solutions employed to examine aggregation.

Preparation of fibrils of α-syn
The α-syn amyloid samples (maximum concentration of 100 μM) were prepared by dissolving α-syn monomer in HEPES (pH 7.4, 20 mM, 150 mM NaCl) at 37°C at 700 rev/min based on the reported paper. To monitor the impact of CeO₂ NPs on protein aggregation, α-syn samples with a single fixed concentration of CeO₂ NPs (40 μg/mL) (as the highest dose which does not show agglomeration) were co-incubated during the preparation of fibrils of α-syn.

ThT fluorescence assay
All fluorescence spectroscopy assays were performed using a Cary Eclipse VARIAN fluorescence spectrophotometer (Varian, CA, USA). Amyloid kinetics was read using ThT as an extrinsic fluorescence probe. The fluorescence intensity was read at regular time intervals with λex and λem at 440 and 480 nm, respectively. Average of the fluorescence intensity of three samples was considered to plot the kinetic study. After dilution of protein samples to 3 μM in the HEPES buffer and addition of ThT solution (15 μM), the kinetic graph was plotted. Afterwards, a sigmoidal fit was used to calculate the kinetic parameters of α-syn amyloid either alone or with CeO₂ NPs based on
the reported equations in previous reports.\textsuperscript{24,25} Briefly, apparent growth rate constant (kapp) and lag phase time were calculated to be 1/\( \tau \) and t\textsubscript{0}−2 \( \tau \), respectively, where t\textsubscript{0} is the time needed to show 50\% of the maximal emission intensity and \( \tau \) is nonlinear regression.\textsuperscript{24,25}

ANS fluorescence assay

The ANS fluorescence study was done to monitor the structural changes of \( \alpha \)-syn species. Aliquots of the \( \alpha \)-syn samples either alone or co-incubated with fixed concentration of CeO\(_2\) NPs were removed at 100 hrs and diluted to a final concentration of 3 \( \mu \)M in HEPES buffer (20 mM, pH 7.4) containing 20 \( \mu \)M ANS. The excitation wavelength with a slit width of 10 nm was fixed at 380 nm, and emission wavelength with a slit width of 5 nm was scanned between 400 and 600 nm.

Congo red binding assay

The experiment was done at room temperature using a Cary Eclipse VARIAN absorbance (Varian, CA, USA) spectroscopy. Briefly, 10 \( \mu \)M of the \( \alpha \)-syn amyloid samples either alone or co-incubated with a single dose of CeO\(_2\) NPs for 100 hrs was added to Congo red solution with a concentration of 20 \( \mu \)M and the absorbance signals were read between 400 and 600 nm.

Far-UV CD measurement

Ellipticity changes of protein samples were monitored employing an AVIV 215 spectropolarimeter (Proterion Corp., USA). Aliquots of the \( \alpha \)-syn samples either alone or co-incubated with a single dose of CeO\(_2\) NPs after 100 hrs were diluted to a final concentration of 10 \( \mu \)M in HEPES buffer (20 mM, pH 7.4). Afterwards, the ellipticity changes were read in the range of 190–260 nm and the percent of the secondary structure of protein samples were calculated using CDNN software (Proterion Corp., USA).

Transmission electron microscopy (TEM) investigation

The morphology of \( \alpha \)-syn amyloid either alone or with CeO\(_2\) NPs was captured using TEM machine with a model of EM10C (Zeiss, 100 KV, Germany). Briefly, 15 \( \mu \)L of protein samples was dropped to a carbon-coated grid and left at room temperature for 15 mins. Afterwards, the morphology of aggregated species was studied using TEM investigation.

Simulation methods

Two spherical CeO\(_2\) clusters of diameters 3 and 2 nm were constructed by repeating the unit cells of CeO\(_2\) crystal and used in the docking and the molecular dynamics simulations, respectively. A ligand-binding study was carried out using HEX 6.3 software.\textsuperscript{26} The molecular dynamic simulations were done using the Forcite code and the universal force field.\textsuperscript{27} All force filed parameters were set to default.

Cell culture

SH-SY5Y cells were obtained from Royan institute and were cultured in DMEM-F12 medium containing FBS (10\%), streptomycin (100 \( \mu \)g/mL), penicillin (100 U/mL), and incubated at 37°C in a 5\% CO\(_2\). 1\times10\(^4\) cells/well were seeded into 96-well plate and the \( \alpha \)-syn samples removed from samples incubated either alone or with a single dose of CeO\(_2\) NPs (40 \( \mu \)g/mL) under amyloidogenic environment added to the cells with a final concentration of 10 \( \mu \)M for protein and 4 \( \mu \)g/mL for NPs and incubated for 24 hrs. Cells exposed to 20 mM HEPES buffer (pH 7.4) were considered as negative control samples.

MTT assay

MTT stock solutions with a concentration of 5 mg/mL were then added to samples for 4 hrs followed by aspiration and addition of DMSO. Finally, the optical density of samples was read at 570 nm using an ELISA reader (Expert 96, Asys Hitch, Ec Austria). Data were reported as the percentage of MTT reduction in comparison with the negative control cells, assuming that the optical density of the negative control cells was 100\%.

Flow cytometry assay

Cell apoptosis and necrosis tests were conducted by flow cytometry with Annexin V-FITC Apoptosis Staining Kit (ab14085, UK) based on the manufacturer’s protocol. Briefly, after treatment of cells with an aliquot of \( \alpha \)-syn in the absence or presence of CeO\(_2\) with a final concentration of 10 \( \mu \)M for 24 hrs, cells were harvested, washed, resuspended in 500 \( \mu \)L of binding buffer, added by 5 \( \mu \)L of Annexin V-FITC for 15 mins in the dark, and added by 10 \( \mu \)L of PI. Afterwards, cell apoptosis and necrosis were analyzed by flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA 95131-1807. USA) with flow 6.3 software.

Real time gene expression assay

The expression amount of (BCL-2) and BAX genes was estimated by real-time PCR analysis based on our previous paper.\textsuperscript{28} TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and RevertAid first-strand cDNA synthesis kit (Takara, Japan) were used to extract total
RNA and synthesis of cDNA, respectively according to the manufacturer’s instructions. The quantitative real-time polymerase chain reaction (qPCR) assay was done using an ABI Step One Sequence Detection System (Thermo Fisher Scientific) by SYBR® Premix Taq™ II (Takara, Japan) using GAPDH as a control.

Statistical analysis
Data were reported as mean ± standard deviation (SD) from three independent experiments. The statistical analysis was carried out using one-way ANOVA. The significance of data was considered as *P ≤ 0.05.

Results
Characterization of NPs
It was depicted that CeO₂ NPs show an average diameter of around 30 nm with a vibration peak at 738 cm⁻¹.22 Indeed, potential transport of therapeutic agents like NPs into the human brain is one of the most demanding tasks in anti-amyloid drug development owing to the blood-brain barrier (BBB). To go across the BBB, the size of NPs as one of the most important factors must be considered. Actually, NPs with a size of less than 50 nm have been shown to provide a well-dispersed state in working solutions, cross the BBB and may provide promising anti-amyloid functions.29,30

ThT fluorescence assay
Fibrillization investigation of the α-syn was done either alone or with CeO₂ NPs at a fixed concentration of 40 µg/mL. The fibrillation process was detected by using ThT fluorescence experiment. The aggregation studies exhibited the features of a representative amyloid fibril plot: a sigmoidal curve with a beginning lag process, where no enhance of fluorescence intensity is detected, because no amyloid species are produced, a quick fibrillation process, where the fluorescence signal enhances as the amyloid species form, and a steady-state process, where the maximum fluorescence intensity does not change significantly. Figure 1A shows the fibrillation plot for the α-syn either alone or with CeO₂ NPs. Table 1 reveals that the lag phase time in the absence of NPs is around 23 hrs, however, it increases to 35.5 hrs in the presence of NPs. Indeed, the free α-syn depicts no fibrillation till 23 hrs, and NP impact is determined in the lag phase time range. In the case of α-syn co-incubated with CeO₂ NPs, the presence of the NPs increases the duration of lag phase time and inhibits the fibrillation process. Also, a reduction in k app was observed in the presence of NPs (Table 1), which suggests the reaction kinetic in the presence of CeO₂ NPs is quite slower than those in the absence of NPs.

ANS fluorescence assay
The amyloid forms of protein are typically distinguished from their monomer species through binding to ANS probe. The partial denaturation of the natively disordered proteins like α-syn and transformation into amyloid structures induces the formation of hydrophobic patches which can bind ANS molecules. This binding leads to an enhancement in ANS fluorescence intensity and a blue shift in λex.31 A comparison of ANS emission intensities of α-syn species (monomer, amyloid either alone or with CeO₂ NPs) is depicted in Figure 1B. As anticipated, the spectra of α-syn monomer and ANS exhibited negligible ANS fluorescence intensity. At amyloid states, the ANS intensity of α-syn was ~3.5 times more than that of monomer species, indicating increased induction of hydrophobic moieties. Besides, the binding of ANS to α-syn in the amyloid state led to a significant blue shift in λ max (Figure 1B). However, a reduction in ANS fluorescence intensity of α-syn amyloid was observed when α-syn monomer co-incubated with CeO₂ NPs during amyloidogenic conditions. The reduction in ANS fluorescence intensity of α-syn amyloid was distinguishable in the presence of CeO₂ NPs. Protein in monomer state showed the maximum intensity of ANS fluorescence at around 500 nm, which decreased to 488 nm and 490 for α-syn amyloid alone and with CeO₂ NPs, respectively. The maximum ANS fluorescence intensity and pronounced blue shift may reveal that amyloid fibril species of α-syn is probably formed. However, co-incubation of α-syn with CeO₂ NPs may inhibit the formation of these amyloid species.

Congo red assay
Congo red assay was performed to evaluate the amyloid fibril formation of α-syn either alone or with CeO₂ NPs. Figure 1C depicts the Congo red absorbance of α-syn in different states. As can be seen, Congo red absorbance and blue shift for α-syn amyloid were highest among all states. However, Figure 1C reveals that Congo red absorbance and blue shift values in α-syn amyloid with CeO₂ NPs were lower than the maximum values for α-syn amyloid in the absence of CeO₂ NPs. Therefore, the amyloid formation of α-syn in amyloidogenic conditions was effectively inhibited by CeO₂ NPs.
The ellipticity changes of a biomolecule in far-UV wavelength (190–250 nm) show a n→π* transition band around 220 nm and a π→π* transition band about 190 nm which arises from peptide bonds. Therefore, CD signals of a biomolecule in this wavelength range can be used to determine the alteration in secondary structure of protein. Far-UV CD bands of different species of α-syn are shown in Figure 1D. α-Syn in monomer state exhibited a minimum at around 195 nm, indicating the dominant random coil conformation in protein structure. The content of secondary structure of α-syn is also tabulated in Table 2. However, for α-syn in the amyloid state, the minima at 195 nm were almost disappeared and shifted toward higher wavelength.

Table 1 Influence of CeO₂ NPs on the kinetics parameters of α-syn fibrillization calculated by ThT fluorescence assay

| Samples          | (Kapp) (h⁻¹) | Lag time (hrs) | Amplitude (a.u.) |
|------------------|--------------|---------------|------------------|
| α-syn            | 0.062        | 23            | 721              |
| α-syn/CeO₂ NPs   | 0.058        | 35.5          | 412              |

Abbreviations: CeO₂, cerium oxide; NPs, nanoparticles; ThT, thioflavin T. 

CD study

The ellipticity changes of a biomolecule in far-UV wavelength (190–250 nm) show a n→π* transition band around 220 nm and a π→π* transition band about 190 nm which arises from peptide bonds. Therefore, CD signals of a biomolecule in this wavelength range can be used to determine the alteration in secondary structure of protein.

Figure 1 Spectroscopic studies of α-syn species either alone or co-incubated with CeO₂ NPs. Notes: (A) Kinetic graph of α-syn fibrillation in the absence and presence of CeO₂ NPs based on ThT assay; (B) ANS fluorescence intensity of different species of α-syn; (C) Congo red absorbance of different species of α-syn; and (D) CD spectra of different species of α-syn. Abbreviations: CeO₂, cerium oxide; NPs, nanoparticles; ThT, thioflavin T; ANS, anilinonaphthalene-1-sulfonic acid; α-syn, α-synuclein; CD, circular dichroism.
value around 217 nm, indicating remarkable loss of random coil structure and acquisition of β-sheet-like structures.\(^{31}\) Afterwards, to explore the inhibitory effect of CeO\(_2\) NPs on amyloid formation, we performed CD experiment for α-syn amyloid/CeO\(_2\) NP complex. Changing the ellipticity values was found in the α-syn amyloid samples co-incubated with CeO\(_2\) NPs, where β-sheet-like structures were profoundly lower than that of amyloid state without NPs (Table 2). A decrease in the content of β-sheet-like structures suggesting that α-syn preserve its secondary structure to some extent in the presence of CeO\(_2\) NPs. Indeed, in comparison to the monomer state of α-syn, where the random coil structure was calculated to be 73.7%, this structure decreased to 19.4% at amyloidogenic condition. However, the secondary structure (% random coil) of α-syn is largely preserved in the presence of CeO\(_2\) NPs.

TEM investigation

TEM study was exploited to observe the morphology of aggregated species. Figure 2 displays TEM images of α-syn monomer as control or incubated for 100 hrs under amyloidogenic conditions either alone or with CeO\(_2\) NPs. As shown in Figure 2A, α-syn monomer does not show any observable aggregated species. Figure 2B demonstrates mature amyloids with typical amyloid fibrils. However, in α-syn samples incubated with 40 μg/mL CeO\(_2\) NPs, generation of such aggregated species with amyloid fibrils morphology were considerably inhibited, with the formation of amorphous appearance (Figure 2C). In other words, in the presence of CeO\(_2\) NPs, the well-defined amyloid structures with amyloid fibrils morphology were lost to view, and instead, amorphous aggregates with different sizes were appeared (Figure 2C). This study also provides interesting data regarding the inhibitory effect of CeO\(_2\) NPs against the amyloid formation.

Molecular docking study

The NMR structure of α-syn (PDB ID: 1XQ8) and α-syn fibrils (PDB ID: 2N0A) were downloaded from the online Protein Data Bank RCSB PDB (http://www.pdb.org). The molecular docking was executed with the larger spherical cluster of CeO\(_2\) (Figure 3). The calculated binding energy for CeO\(_2\) nanocluster with α-syn fibrils (Figure 3A) and α-syn monomer (Figure 3B) was −141.98 and −199.35 E-value, respectively. Indeed, it may be suggested that the affinity of CeO\(_2\) nanocluster to α-syn monomer is more than α-syn fibrils. Visualization of the binding site was performed by using CHIMERA (www.cgl.ucsf.edu/chimera) and PyMOL (http://pymol.sourceforge.net/) tools, as shown in Figure 3C. As can be seen in Figure 3C, the most attractive residues of α-syn fibrils are Ala-76, Val-77, Ala-90, Ala-89, and Ile-88. However, for α-syn monomer, the most attractive sites are Met-1, Asp-2, Met-5, Lys-6, Ser-8 (Figure 3D).

| Protein state      | Random coil % | α-helix % | β-sheet % | Turn and loop % |
|--------------------|---------------|-----------|-----------|-----------------|
| Monomer            | 73.7          | 11.9      | 4.5       | 9.9             |
| Amyloid            | 19.4          | 7.5       | 61.3      | 11.8            |
| Amyloid/CeO\(_2\) NP | 38.9          | 11.3      | 39.4      | 10.4            |

Abbreviations: α-syn, α-synuclein; CeO\(_2\), cerium oxide; NP, nanoparticle.

Table 2 The structural characteristics of α-syn at different states

Figure 2 TEM images of different species of α-syn.
Notes: (A) α-syn monomer; (B) α-syn amyloid; and (C) α-syn amorphous aggregates in the presence of CeO\(_2\) NPs.
Abbreviations: TEM, transmission electron microscopy; α-syn, α-synuclein; CeO\(_2\), cerium oxide; NPs, nanoparticles.
Figure 3 Theoretical studies of interaction between CeO$_2$ nanocluster and different species of α-syn.

Notes: (A) Molecular docking of CeO$_2$ nanocluster with α-syn fibrils; (B) molecular docking of CeO$_2$ nanocluster with α-syn monomer; (C) visualization of docked pose of CeO$_2$ nanocluster with α-syn fibrils; (D) visualization of docked pose of CeO$_2$ nanocluster with α-syn monomer; (E) the conformation of α-syn amyloid in the beginning; and (F) and after 1 ns evolution exploited by molecular dynamic study.

Abbreviations: CeO$_2$, cerium oxide; α-syn, α-synuclein.
Therefore, it may be identified that as Ala, Val, and Ile are hydrophobic residues, the interaction of CeO\textsubscript{2} nanocluster with α-syn amyloid is done through hydrophobic forces. However, due to the dominant hydrophilic residues (Asp, Lys, Ser) in the binding site of the α-syn monomer with CeO\textsubscript{2} nanocluster, the hydrophilic interaction such as electrostatic forces and hydrogen binding is mostly involved in the complex formation between nanocluster and α-syn in the monomer state.

**Molecular dynamics study**

Molecular modeling was carried out to explore the conformational changes of α-syn in the presence of CeO\textsubscript{2} NPs. Two α-syn amyloid structures and five clusters of CeO\textsubscript{2} were covered by water molecules. The NVE ensemble with a time step of 1 fs was exploited in the molecular modeling simulation. The conformation of α-syn amyloid in the beginning and after 1 ns evolution was exhibited in (Figure 3E and F). As can be observed, the neighboring protein chains have a distance of 5.576 Å at the beginning of the simulation (Figure 3E). However, this distance increased to 6.120 Å in the presence of CeO\textsubscript{2} NPs, indicating that the amyloid structure of α-syn is partially dis-aggregated (Figure 3F). These data are in good agreement with our spectroscopic outcomes which showed an inhibitory effect of CeO\textsubscript{2} NPs against the amyloid formation of α-syn.

**MTT assay**

MTT assay was done to investigate the toxicity of aggregated species of α-syn either alone or with CeO\textsubscript{2} NPs. As shown in Figure 4, α-syn monomer with a concentration of 10 μM and CeO\textsubscript{2} NPs with a concentration of 4 μg/mL do not trigger significant toxicity against SH-SY5Y cells after 24 hrs. However, incubating cells with α-syn amyloid with a concentration of 10 μM trigger significant toxicity against cells, which reduce the cell viability to 29.08±5.36% (**P<0.001, relative to negative control cells). Afterwards, it was seen that incubating cells with α-syn amyloid/NP complex with the same concentration, recovered the cell viability to 59.79±10.27% (**P<0.05, relative to α-syn amyloid-treated cells). These data indicated that formed aggregates in the presence of CeO\textsubscript{2} NPs are significantly less toxic in comparison with α-syn amyloids in the absence of NPs.

**Flow cytometry analysis**

Cultured SH-SY5Y cells were treated with 10 μM of α-syn amyloid either alone or with CeO\textsubscript{2} NPs and flow cytometry analysis was done to quantify the apoptosis and necrosis. As displayed in Figure 5A, control cells show no significant apoptosis or necrosis. However, α-syn amyloid significantly increased the percent of early apoptosis (22.2%, **P<0.01), late apoptosis (16.7%, ***P<0.001), and necrosis (7.0%, **P<0.01) relative to the control group (Figure 5B). In another side, α-syn amyloid co-incubated with CeO\textsubscript{2} NPs showed higher level of viability and reduced amount of early apoptosis (7.5%, ##P<0.01), late apoptosis (6.6%, ###P<0.01), and necrosis (3.9%, ##P<0.05) relative to α-syn amyloid-treated group, suggesting the inhibiting role of CeO\textsubscript{2} NPs against induced cytotoxicity by α-syn amyloids (Figure 5C).

**Real-time PCR**

qPCR was also employed to investigate the mRNA levels of apoptotic markers (Bcl-2, and Bax) in SH-SY5Y cells exposed to α-syn samples incubated with or without CeO\textsubscript{2} NPs for 100 hrs. Data indicated that the mRNA expression of these apoptotic genes was markedly changed in SH-SY5Y cells due to α-syn amyloid exposure. While no increase in relative ratio of Bax/Bcl-2 mRNA level was observed for control samples, relative ratio of Bax/Bcl-2 mRNA level increased significantly after 24 hrs exposure to α-syn amyloid fibrils (**P<0.05) (Figure 6). However, in the present of CeO\textsubscript{2} NPs, the relative ratio of Bax/Bcl-2 mRNA level was reduced to 1.28±0.11% (##P<0.05)
(Figure 6), indicating that formed aggregated species are relatively less toxic compared to α-syn amyloids in the absence of NPs.

Discussion

Recent studies by Mohammad-Beigi et al.,32 revealed that the different shape of α-syn fibrils is formed after aggregation due to the difference in β-sheet folding, the molecular accumulation between the sheets levels and the interaction of lateral chains in the environment. Indeed, even slight variations in environmental conditions such as changes in pH, temperature, ions concentration, nano-objects concentrations, and drug concentrations can strongly affect the aggregation and folding processes of α-syn. Therefore, by identifying any of the factors and their effects on the accumulation of α-syn, in addition to predicting the different forms of aggregation, it is possible to prevent the α-syn accumulation. One of the most effective factors in reducing α-syn aggregation is the reduction of the ROS that can be achieved by the activity of antioxidant enzymes. In this regard, Murakami et al.,33 showed that depletion of the activity of SOD in mice increases the accumulation of amyloid plaques. In this line, CeO₂ NPs are considered to be an appropriate option for preventing the accumulation of amyloids due to the SOD and CAT-like properties.34 In this study, we have exhibited that CeO₂ NPs may be one of the environmental factors that reduce the accumulation of α-syn amyloid fibrils. In agreement with our findings, Cimini et al.,35 determined that the CeO₂ NPs modified with PGE and anti-βψ, in addition to the detection of amyloid βψ, reduced their aggregation connected with the antioxidant properties of CeO₂ NPs. Analogously, in the cortical neurons cell model isolated from Sprague-Dawley rat embryos, Dowding et al.,36 using CeO₂ NPs could prevent mitochondrial fragmentation and cell death by decreasing the level of Aβ-amyloid derived from peroxidase and peroxynitrite-like properties. At the same time, it was found that the use of CeO₂ NPs reduces the rate of development of AD relied on the reduction of amyloid levels through peroxidase-like activity.37 In this line, Kaushik, Bharadwaj, Kumar, Wei3 in a computational model showed that CeO₂ NPs, based on their antioxidant properties could be used as a potential inhibitor of α-Syn accumulation. Whereas, Sekar, Kumar, Mukherjee, Chandrasekaran38 reported that CeO₂ NPs play a promoting role in the formation of HSA fibrillation via the enhancement of β-sheet structures in protein conformation.

Besides, in the present study, it was observed that CeO₂ NPs at 40 μg/mL could increase the lag phase time of α-syn fibrillation, indicating a decrease in fibrillation levels. This finding, in concurrence with the findings of John et al.,39 described that Au NPs with polymeric coatings and small molecules inhibit amyloid accumulation by increasing the lag phase time. On the other hand, our cellular results indicate that CeO₂ NPs can have a significant effect on the survival of host cells in the presence of toxic species of α-syn amyloid. We found that CeO₂ NPs reduce cytotoxicity by decreasing α-syn accumulation. In this regard, conflicting reports are due to the type of NPs and protein. A group of NPs increase protein aggregation and cytotoxicity, and others with antioxidant activity or surface modification decrease protein accumulation and
their associated cytotoxicity. For example, Mandal, Debnath, Jana, Jana showed that by modifying the surface of Au NPs with trehalose, the amount of protein aggregation decreases, and hence cytotoxicity is greatly reduced. While, it has been shown that the interaction of insulin with zinc oxide NPs results in the structural reconstruction of amyloid clusters and associated cytotoxicity. Nevertheless, Samai, Basu, Mati, Bhattacharya recently used bare CeO$_2$ NPs, CeO$_2$ NPs coated with folic acid (CeO$_2$-FA NPs), and CeO$_2$ NPs coated with polyacrylic acid (CeO$_2$-PAA NPs) to prevent the aggregation of lysosomes and amyloid growth. Their results revealed that not only the highest amyloid aggregation blockage was related to CeO$_2$-PAA NPs and CeO$_2$-FA NPs compared to bare CeO$_2$ NPs, but also significantly reduced the level of cytotoxicity relative to the control group. Therefore, with the change of surface charge from positive to negative by some coatings, the level of protein aggregation or amyloid-fibrillation along with cytotoxicity can be greatly reduced. In this regard, Javdani, Rahpeyma, Ghasemi, Raheb exhibited that the change in the surface charge of iron NPs from positive to negative by dextran would reduce amyloid-fibrillation in both β-amyloids and α-syn.

**Conclusion**

In the present study, CeO$_2$ NPs were shown to inhibit the formation of α-syn amyloid fibrils-associated cytotoxicity against SH-SY5Y cells. Spectroscopic and theoretical studies demonstrated that CeO$_2$ NPs bind to α-syn monomer and increase the lag phase time of amyloid fibril formation. Also, it was shown that the aggregated species formed by α-syn with CeO$_2$ NPs are relatively less toxic compared to amyloid fibrils formed in the absence of CeO$_2$ NPs. These outcomes hold a great promise for helping in tackling the challenges related to the therapeutic efficiency of NPs in neurodegenerative diseases.

**Acknowledgment**

This article was made possible by the grant GCC-2017-005 under the GCC collaborative research Program from Qatar University, and the grant by Islamic Azad University of Tehran Medical Sciences, Tehran, Iran. All statements in the article are sole responsibility of the authors.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Marei HE, Althani A, Lashen S, Cenciarelli C, Hasan A. Genetically unmatched human iPSC and ESC exhibit equivalent gene expression and neuronal differentiation potential. *Sci Rep*. 2017;7(1):17504–17510. doi:10.1038/s41598-017-17882-1

2. Wills J, Credle J, Haggerty T, Lee J-H, Oaks AW, Sidhu A. Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson’s disease. *PLoS One*. 2011;6(3):e17953–9. doi:10.1371/journal.pone.0017953

3. Kaushik AC, Bharadwaj S, Kumar S, Wei D-Q. Nano-particle mediated inhibition of Parkinson’s disease using computational biology approach. *Sci Rep*. 2018;8(1):9169–9179. doi:10.1038/s41598-018-27580-1

4. Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. *Prog Neurobiol*. 2016;147:1–19. doi:10.1016/j.pneurobio.2016.07.005

5. Elmann A, Telerman A, Ofir R, Kashman Y, Lazarov O. β-amyloid cytotoxicity is prevented by natural achillolide A. *J Nat Med*. 2018;72(3):626–631. doi:10.1007/s11418-018-1191-0

\[ \text{Figure 6} \] Changes in the Bax/Bcl-2 ratio (of the mRNA levels) in all treated cases relative to control group.

**Notes:** *P*-value <0.05 relative to control sample; #*P*-value <0.05 relative to α-syn amyloid sample.

**Abbreviation:** α-syn, α-synuclein.
6. Fink AL. The Aggregation and fibrillation of α-synuclein. Acc Chem Res. 2006;39(9):628–634. doi:10.1021/ar050787t

7. Adamczyk A, Solecka J, Strosznajder J. Expression of α-synuclein in different brain parts. J Physiol Pharmacol. 2005;56(1):29–37.

8. Panza F, Louzopone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(1):1–10.

9. Alvarez YD, Fauser BCJ, Pellegrini JV, Jovin TM, Jares-Erijman EA, Stafne SD. Influence of gold nanoparticles on the kinetics of alpha-synuclein aggregation. Nano Lett. 2013;13(12):6156–6163. doi:10.1021/nl403490e

10. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev. 2011;111(2):253–280. doi:10.1021/cr1001832

11. Padmanabhan P, Kumar A, Kumar S, Chaudhary RK, Gulyas B. Nanoparticles in practice for molecular imaging-applications: an overview. Acta Biomater. 2016;41:1–16. doi:10.1016/j.actbio.2016.06.003

12. Mohammadi S, Nikhmeh M. TiO2 nanoparticles as potential agents of fibrillation of α-synuclein, a Parkinson’s disease-related protein. Iran J Biotechnol. 2017;15(2):87–97. doi:10.15171/ijb.1519

13. Wu J, Wang C, Sun J, Xue Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano. 2011;5(6):4476–4489. doi:10.1021/nn103530b

14. Naz S, Beach J, Heckert B, et al. Cerium oxide nanoparticles: a ‘radical’ approach to neurodegenerative disease treatment. ACS Nano. 2017;12(5):545–553. doi:10.1021/acsnano.6b03999

15. Paul A, Hasan A, Rodes L, Metz J, Lelouche J-M, Popovtzer R. The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model. J Nanobiotechnology. 2015;13(1):19–29. doi:10.1186/s12951-015-0075-7

16. Qadeer A, Rabbari G, Zaidi N, Ahmad E, Khan JM, Khan RH. 1-Anilino-8-naphthalene sulfonate (ANS) is not a desirable probe for determining the molten globule state of chymopapain. PLoS One. 2012;7(11):e50633. doi:10.1371/journal.pone.0050633

17. Mohammad-Beigi H, Hosseini A, Adeli M, et al. Mechanistic understanding of the interactions between nano-objects with different surface properties and α-synuclein. ACS Nano. 2019;13(1):1–10.

18. Morakami K, Murata N, Noda Y, et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem. 2011;286(52):44557–44568. doi:10.1074/jbc.M111.279208

19. Dowding JM, Dosani T, Kumar A, Seal S, Self WT. Cerium oxide nanoparticles scavenge nitric oxide radical (NO). Chem Commun (Camb). 2012;48(40):4896–4898. doi:10.1039/c2cc23045f

20. Ciminì A, D’Angelo B, Dass S, et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater. 2012;8(6):2056–2067. doi:10.1016/j.actbio.2012.01.035

21. Dowding JM, Song W, Bossy K, et al. Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ. 2014;21(10):1622–1632. doi:10.1038/cdd.2014.72

22. Seal S, Dass S, Ciminì A, D’Angelo B. Nanoparticles of cerium oxide targeted to an amyloid beta antigen of alzheimer’s disease and associated methods. Google Pat. 2016;1:1.2.

23. Sekar G, Kumar NP, Mukherjee A, Chandrasekaran N. Cerium oxide nanoparticles promote HSA fibrillation in vitro. Int J Biol Macromol. 2017;103:1138–1145. doi:10.1016/j.ijbiomac.2017.05.180

24. John T, Gladysz A, Kabeil C, Martin LL, Risselada HJ, Abel B. Impact of nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles. Nanoscale. 2018;10(45):20894–20913. doi:10.1039/c8nr04506b

25. Mandal S, Debnath K, Jana NR, Jana NR. Trehalose-functionalized gold nanoparticle for inhibiting intracellular protein aggregation. Langmuir. 2017;33(49):13996–14003. doi:10.1021/acs.langmuir.7b02202

26. Asnath S, Haraizka Z, Nayak PS, et al. Insulin adsorption onto zinc oxide nanoparticle mediates conformational rearrangement into amyloid-prone structure with enhanced cytotoxic propensity. Biochim Biophys Acta Gen Subj. 2019;1863(1):153–166. doi:10.1016/j.bbagen.2018.10.004

27. Samal B, Basu A, Mati SS, Bhattacharya SC. Antiamyloid activity of functionalized cerium oxide nanoparticle on lysozyme fibrillation: spectroscopic and microscopic investigation. Material. 2019;6:100285–100295. doi:10.1039/c9mta00000a

28. Javdani N, Rahpeyma SS, Ghasemi Y, Rahb J. Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process. Int J Nanomedicine. 2019;14:799–808. doi:10.2147/IJN.S190354

29. Ritchie DW, Venkataraman V. Ultra-fast FFT protein docking on graphics processors. Bioinformatics. 2010;26(19):2398–2405. doi:10.1093/bioinformatics/btp444

30. Rappé AK, Casewitz CJ, Colwell K, Goddard WA III, Skiff WM. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc. 1992;114(25):10024–10035. doi:10.1021/ja00051a040

31. Babadagli MMN, Moghaddam MF, Sollivan S, et al. Biophysical, bioinformatic, cellular, and molecular investigations on the effects of graphene oxide nanosheets on the hemoglobin structure and lymphocyte cell cytotoxicity. Int J Nanomedicine. 2018;13:6871–6877. doi:10.2147/IJN.S174048

32. Hanada S, Fujioka K, Inoue Y, Kanaya F, Manome Y, Yamamoto K. Cell-based in vitro blood–brain barrier model can rapidly evaluate nanoparticles’ brain permeability in association with particle size and surface modification. Int J Mol Sci. 2014;15(2):1812–1825. doi:10.3390/ijms15021825

33. Shilo M, Sharon A, Baranes K, Motiei L, Lelouche J-PM, Popovtzer R. The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model. J Nanobiotechnology. 2015;13(1):19–29. doi:10.1186/s12951-015-0075-7
